6,14-endoetheno northebaines and nororipavines



United States Patent US. Cl. 260285 7 Claims ABSTRACT OF THE DISCLOSURE The invention relates to novel thebaine and oripavine derivatives of the formula MeO wherein Y, R, R R R and R are hereinafter specified radicals, and pharmaceutically acceptable salts thereof.

The compounds of the invention are therapeutically useful. The invention also includes pharmaceutical compositions comprising a novel compound or a pharmaceutically acceptable salt thereof and a carrier therefor, which may be in unit dosage form.

This invention relates to novel derivatives of thebaine and oripavine, their pharmaceutically acceptable salts, and to processes for their production.

According to the present invention there are provided compounds of the following formula, and pharmaceutically acceptable salts of compounds of the said formula:

. Patented Sept. 2, 1969 in which:

Y is the etheno (CH=CH) or the ethano R is methyl or hydrogen;

R is a hydrogen atom, an alkyl or alkenyl group of up to 3 carbon atoms a phenyl or a tolyl group;

R is a cycloalkyl group of 5 to 7 carbon atoms, an alkyl or alkenyl group of up to 8 carbon .atoms, a benzyl or a phenethyl group;

R is a hydrogen atom, an alkyl group of up to 5 carbon atoms, an allyl, methylallyl, dimethylallyl, crotyl or pro pargyl group, or a cycloalkyl methyl group of 4 to 6 carbon atoms;

R is a phenyl group, a tolyl group, a cycloalkyl group of 5 to 7 carbon atoms, an alkyl or alkenyl group of up to 5 carbon atoms, a propargyl group, a benzyl or a phenethyl group.

The compounds of the Formula I in which R =an alkyl group, an alkenyl group and cycloalkyl methyl group as hereinbefore defined, i.e., the compounds of the formula:

in which R, R R R and Y are as defined hereinbefore and in which R is an alkyl group of up to 5 carbon atoms, an 'allyl, methylallyl, dimethylallyl or crotyl group or a cycloalkyl methyl group of 4 to 6 carbon atoms, may be prepared from the compounds of the formula:

in which R, R R R and Y are as defined hereinbefore, and Z is the anion from an acid, preferably from hydrochloric or perchloric acid, by reaction with an organometallic compound, a Grignard reagent R MgX or an organo lithium compound R Li, where X is a halogen. The compounds of Formula II are described in our concurrently filed application No. 715,497.

The compounds of Formula II are the iminium salts of the compounds of the formula:

which are prepared by the dehydrogenation of compounds of the formula for example by reacting in aqueous acetic acid with mercuric oxide or mercuric acetate.

The compounds of Formula IA in the special case in which R =R and/or R may be prepared from compounds of the formula:

in which Q is in which R, R R R and Y are as hereinbefore defined, by reaction with organometallic compounds, for example a Grignard reagent R MgX or an organo lithium compound R Li. Similarly compounds of Formula IA in the special case in which R =R =R may be prepared from compounds of Formula V in Which Q is in which Alk is alkyl of up to 5 carbon atoms, by reaction with an organo metallic compound for example Grignard reagent R MgX or an organo lithium compound R Li. The compounds of Formula V are described in our abovementioned application No. 715,497.

The bases of Formula I in which R is methyl and R is cyano (CN) may be prepared from those in which R is methyl by treatment with cyanogen bromide.

The bases of Formula I in which R is methyl and R is hydrogen may be prepared from those in which R is cyano by alkaline hydrolysis, preferably with an alkali metal hydroxide in a solvent such as diethylene glycol at a temperature of about ISO-170 C. Compounds in which R and R are both hydrogen can be prepared by carrying out this hydrolysis at temperatures above 180 C., preferably about ZOO-210 C.

The bases of Formula I in which R is alkyl, alkenyl or alkynyl may also be prepared from those in Which R is hydrogen by treatment with the appropriate alkyl, alkenyl or alkynyl halide. The bases in which R is alkyl, alkenyl, alkynyl or cycloalkyl methyl can further be prepared from bases in which R is hydrogen by acylation with the appropriate acid chloride or anhydride followed by reduction of the resulting amide with lithium aluminium hydride.

The bases of Formula I in which R is hydrogen and R is other than cyano can be prepared from the corresponding bases in which R is methyl by heating with an alkali metal hydroxide or alkoxide in a suitable solvent such as diethylene glycol at a temperature above 180 C preferably about ZOO-210 C.

The invention is further illustrated by the following examples:

Example 1.6,14-endoetheno-7-( l-hydroxy-l-methylethyl)-16-methyltetrahydrothebaine (a) A solution of methylmagnesium iodide in ether (25 ml.) was prepared from methyl iodide (1.9 ml.) and magnesium (1.1 g.). A slurry of 7-acety1-16-dehydro- 6,l4-endoethenotetrahydrothebaine perchlorate (3.8 g.) in ether (25 ml.) was added in portions, and when the initial vigorous reaction had subsided, the mixture was boiled under reflux for 4 hours. The cooled solution was treated with ammoniacal ammonium chloride solution and extracted with ether to give the 16-methyl-compound (2.4 g.), M.P. -142 after crystallization from aqueous methanol.

Analysis.Calcd. for C H NO C, 73.0; H, 8.1. Found: C, 72.8; H, 8.1%.

(b) A solution of methylmagnesium iodide in ether ml.) was prepared from methyl iodide (25 m1.) and magnesium (8.5 g). A slurry of 16-dehydro-6,14-endoetheno 7 l-hydroxy-l-methylethyl)-tetra-hydrothebaine perchlorate (25 g.) in ether (150 ml.) was added portionwise and when the initial vigorous reaction had subsided the mixture was boiled under reflux for 18 hours. The

cooled solution was treated with ammoniacal ammonium chloride solution and extracted with ether togive the 16-methyl-compound (17 g.), M.P. 140-142", identical with the material obtained in (a) above,

(c) A solution of methyl lithium (4 millimoles) and 16-dehydro 6,14 endoetheno 7 (l-hydroxy-l-methylethyl)-tetrahydrothebaine perchlorate (0.5 g.) in ether ml.) was boiled under reflux for 18 hours. The cooled solution was treated with ammoniacal chloride solution and extracted with ether to give the 16-methyl-c0mpound, M.P. 140-142 alone or mixed with the material obtained in (a) above. Yield 50%.

Example 2.7-( l-cyclohexyll-hydroxyethyl -6, 14-endoetheno-16-methyl-tetrahydrothebaine A solution of methylmagnesium iodide in ether (100 ml.) was prepared from methyl iodide (1.2 ml.) and magnesium (0.68 g.). 7-(l-cyclohexyl-1-hydroxyethyl)- 16 dehydro-6,14-endoethenotetrahydrothebaine perchlorate (2 g.) was added portionwise and when the initial vigorous reaction had subsided the mixture was boiled under reflux for 6 hours. The cooled solution was treated with ammoniacal ammonium chloride solution and extracted with ether to give the 16-methyl-compound which crystallized from ethanol as prisms (1.4 g.), M.P. 182- 185.

Analysis.Calcd. for C H NO C, 75.1; H, 8.6. Found: C, 74.5; H, 8.7%.

Example 3 .6, 14-endoetheno-7- l-hydroxy-l-methylpentyl)-16-methyl-tetrahydrothebaine 16 dehydro 6,14-endoetheno-7-(l-hydroxy-l-methylpentyl)-tetrahydrothebaine hydrochloride (0.5 g.) was added to a solution of methyl magnesium iodide prepared from methyl iodide (1.1 ml.) and magnesium (0.2 g.) in ether (20 ml.) and the mixture boiled under reflux for 18 hours. The cooled solution was decomposed with ammoniacal ammonium chloride solution and extracted with ether. Evaporation of the ether and crystallization of the residue from ethanol gave the l6-methyl-compound, M.P. 118120. Yield 55%.

Analysis.Calcd. for C H NO C, 74.2; H, 8.7. Found: C, 74.6; H, 8.7%.

Example 4.6, l4-endoetheno-7-( l-hydroxy-l-methylethyl) -1G-methyI-tetrahydro-oripavine A mixture of 6,14-endoetheno-7-(l-hydroxy-bmethylethyl)-16-methyltetrahydrothebaine (4.1 g.) and potassistirred and heated at 210 in an atmosphere of nitrogen for 2 hours. The cooled mixture was poured onto ice and the solution was saturated with ammonium chloride and extracted with chloroform. Evaporation of the chloroform and crystallization of the residue from ethanol gave the phenol (2.8 g.), M.P. 235-241 (with partial sublimation and change of crystalline'form).

Analysis.Calcd. for C H NO C, 72.5; H, 7.9. Found: C, 73.1; H, 8.0%.

Example 5 .N-cyano-6, l4-endoetheno-7 l-hydroxy-lmethylethyl) -16-methyltetrahydronorthebaine 6. 6,14 endoetheno 7 (l-hydroxy-l-methylethyl)-l6- methyl-tetra-hydrothebaine (16 g.) cyanogen bromide (6 g.) and methylene chloride (250 ml. were boiled under reflux for 48 hours. Evaporation of the solvent and crystallization of the residue from aqueous ethanol gave the N-cyano-nor-compound (8 g.), M.P. 199-20l.

Analysis.Calcd. for C H N O C, 71.1; H, 7.2; N, 6.6. Found: C, 71.0; H, 7.1; N, 6.8%.

Example 6.--6, l4-endoetheno-7-( l-hydroxy-l-methylethyl) -1 6-methyl-tetrahydronorthebaine and potassium hydroxide (12 g.) in digol (100 ml.) at

170 was stirred for 1 hour in an atmosphere of nitrogen. The cooled solution was poured onto ice and extracted with chloroform. The residue after evaporation of the chloroform was taken up in ether and washed thrice with dilute hydrochloric acid. The combined aqueous washings werebasified with potassium carbonate and the product was isolated by extraction with chloroform to give the nor-base (2.3 g.) characterised as the hydrochloride, M.P.

Analysis.Calcd. for C H NO .HCl. /2H O: C, 65.1; H, 7.5; Cl, 8.0. Found: C, 64.9; H,7.5; C1, 8.0%.

Example 7 .N-allyl-6, 14-endoetheno-7-( l-hydroxy-lr'nethylethyl) -16-methyltetrahydronorthebaine A mixture of 6,14-endoetheno-7-(l-hydroxy-l-methylethyl)-16-methyltetrahydronorthebaine (2.8 g.), allyl bromide (2.1 ml.), anhydrous potassium carbonate (4 g.) and acetone (20 ml.) was stirred and boiled under reflux for 18 hours. The mixture was diluted with water and acidified with hydrochloric acid. After washing the aqueous solution with ether, it was basified with ammonia and extracted with ether to give the N-allyl compound which crystallized from petroleum ether (B.P. -80) as prisms (1.4 g.) M.P. 109111.

Analysis.Calcd. for C H NO Found: C, 73.9; H, 7.8%.

The hydrochloride had M.P. 300.

Analysis.Calcd. for C H NO .HCl: C, 68.4; H, 7.7; CI, 7.5. Found: C, 68.4; H, 7.5; CI, 8.0%;- i

In the following table relating to further examples of compounds of the Formula I, in the column headed Y, A is the etheno group and B represents the ethano group.

60 um hydroxide (12 g.) in dethylene glycol 100 ml.) was 1 1 the dose given. The dose required to-inhibit the number of coughs by 50% was determined.

The results obtained are set out below:

Example No.: ED mg./kg. 2 1.8 3 6.4 31 0.54 Codeine 30 Morphine 7.5

The compounds having antitussive activity may be incorporated into suitable formulations for oral administration, such as a linctus or a pastille. The unit dose of such a formulation may be from 0.5 to 15 mg., for a compound such as that of Example 2, and from 0.1 to 5 mg., for one such as that of Example 31. The following is an example of a linctus having antitussive activity.

Dose: 5 or ml.

When mixed with suitable excipients or diluents, the compounds of this invention can be prepared as pills,

capsules, tablets, powders, solutions, suspensions and the MeO wherein:

R is methyl or hydrogen; R is hydrogen, alkly or alkenyl of up to 3 carbon atoms,

phenyl or tolyl;

12 R is cycloalkyl of 5 to 7 carbon atoms, alkyl or alkenyl of up to 8 carbon atoms, benzyl or phenetliyl; R is hydrogen, alkyl of up to 5 carbon atoms, allyl,

methylallyl, dimethylallyl, crotyl, propargyl, or cyclo- 5 alkyl methyl of 4 to 6 carbon atoms;

' R is phenyl, tolyl, cycloalkyl of 5 to 7 carbon atoms, alkyl or alkenyl of up to 5 carbon atoms, propargyl, benzyl or phenethyl,- or a pharmaceutically acceptable salt;the'reof. 1

2. A compound as claimed in claim 1 whereinzi R is methyl or hydrogen; j

R is methyl; 5 1

R is alkyl of up to 5 carbon atoms, cycloalkyl with 5 to 7 carbon atoms, benzyl or phenethyl;

R is methyl, and p R is alkyl of up to 4 carbon atoms, or a pharmaceutically acceptable saltthereof. 3. 7 -(1.- cyclohexyl-l-hydroxyethyl)-6,l4-endoetheno- 16-rnethyl-tetrahydrothebaine. 1

4. 6,14 endoetheno-7-(l-hydroxy-l-methylpentyl)-l6- methyltetrahydro thebaine.

5. 6,14 endoetheno 7 (l-benzyl-l-hydroxyethyl) 16- methyl-tetrahydrothebaine. 6. 6,1;4 endoetheno-7-(1 cyclohexyl-l-hydroxyethyl)- l6-methyl-tetrahydro-oripavine. f

7. N-cyclopropylmethyl 6 ,14 endoetheno-7-(l-hydroxy-l-methylpropyl)-16-methyl-tetrahydronorthebaine.

References Cited UNITED STATES PATENTS 3,285,914 11/1966 Gordon 260-2 85 3,329,682 7/1967 Bentley 260285 FOREIGN PATENTS 7/ 1967 Netherlands.

OTHER REFERENCES Bentley et. al.: Jour. Am. Chem. Soc., vol. 89, pp. 3267-73 (1967). 40 Bentley et. al.: Jour. Am. Chem. Soc., vol. 89, pp. 3273-80 (1967).

Bentley et. al.: Jour. Am. Chem. Soc., vol. 89, pp. 3281-92 (1967).

Bentley et. al.: Jour. Am. Chem. Soc., vol. 89, pp. 3293-3303 (1967).

Bentley et. al.: Jour. Am. Chem. Soc., vol. 89, pp. 3303-11 (1967).

Bentley et. al.: Jour. Am. Chem. Soc., vol. 89,

DONALD G. DAUS, Primary Examiner US. Cl. X.R. 260696; 424260 

